The transforming growth factor-b (TGF-b) signaling pathway subserves an essential tumor suppressor function in various cell types. A heteromeric complex composed of TGF-b type I (RI) and type II (RII) receptors is required for TGF-b signaling. We have identi®ed a subset of human gastric cancer cell lines which are insensitive to TGF-b and which express a low level of TGF-b type I receptor mRNA relative to a gastric cancer cell line which is highly responsive to TGF-b. Using these cells, we show that hypermethylation of a CpG island in the 5' region of the TGF-b RI gene provides another potentially important mechanism of escape from negative growth control by TGF-b. This hypermethylation was found in four of ®ve human gastric cancer cell lines and ®ve out of 40 (12.5%) primary tumors examined. In human gastric cancer cell lines, treatment with the demethylating agent, 5-aza-2'-deoxycytidine, resulted in increased expression of the TGF-b RI gene, but not the RII gene. Transient transfection of an RI expression vector into the TGF-b resistant SNU-601 cell line restores TGF-b responsiveness. These ®ndings suggest that one of the mechanisms of escape from autocrine or paracrine growth control by TGF-b during carcinogenesis could involve aberrant methylation of CpG islands in the 5' region of the TGF-b RI gene.
Introduction
Transforming growth factor-b (TGF-b) has been described as the prototypical multifunctional cytokine, participating in the regulation of vital cellular activities such as proliferation and dierentiation as well as a number of basic physiological functions such as embryonic tissue and organ development, wound healing, and immunity (Roberts and Sporn, 1990; MassagueÂ , 1990; MassagueÂ et al., 1994) . Another essential function of TGF-b, which has recently come to light, is its role as a tumor suppressor in a variety of dierent human cell types (Kim and Kim, 1996; Markowitz and Roberts, 1996) . Human cancer cells frequently demonstrate resistance to the normal growth inhibitory eects of TGF-b, and it has been proposed that development of such TGF-b resistance represents a signi®cant step in the process of carcinogenesis. The ®rst correlation between TGF-b resistance in cancer cells and speci®c genetic defects was the identi®cation of frequent structural alterations of the TGF-b type II receptor (TGF-b RII) gene in a series of human gastric cancer cell lines (Park et al., 1994; Chang et al., 1997) . Subsequently, a characteristic frameshift mutation in the TGF-b RII gene was recognized in a large portion of colon cancer specimens obtained from patients with the hereditary nonpolyposis colon cancer (HNPCC) syndrome Myero et al., 1995; Parsons et al., 1995) . However, a strong correlation between TGF-b RII mutation and microsatellite instability has been demonstrated, only for colon and gastric cancers (Eshleman and Markowitz, 1995; Kolodner, 1996; Markowitz et al., 1995; Modrich and Lahue, 1996; Myero et al., 1995; Parsons et al., 1995) . Since then, defective expression of TGF-b RII has been demonstrated in gastric, colon, small-cell lung, breast, endometrial, hepatocellular, bladder, and squamous cell cancers as well as retinoblastoma, pheochromocytoma, osteosarcoma, and lymphomas (Chang et al., 1997; Garrigue-Antar et al., 1995; Inagaki et al., 1993; Kadin et al., 1994; Kim and Kim, 1996; Kimchi et al., 1988; Park et al., 1994; Markowitz et al., 1995; Markowitz and Roberts, 1996; Sun et al., 1994; Wang et al., 1995) .
The two human gastric cancer cell lines used for this study, SNU-484 and SNU-601, demonstrated TGF-b resistance but contained no discernible alterations in the TGF-b RII gene (Park et al., 1994) . To explore the possibility that other genetic defects may be involved in the development of TGF-b resistance during the process of malignant progression, we analysed the speci®c nucleotide sequence for the TGF-b type II (RII) and type I receptor (RI) genes in ®ve dierent human gastric cancer cell lines including SNU-601. With the exception of SNU-484 and SNU-601, each of the TGF-b resistant cell lines demonstrated speci®c mutations of the TGF-b RII gene. Sequence analysis of SNU-484 and SNU-601 revealed wild type TGF-b RI and RII. Cell lines with structurally altered RII also express a low level of RI mRNA, suggesting that some abnormalities of transcriptional regulation or altered mRNA processing or stability might be involved.
In the present study, we have examined the possibility that methylation changes in the CpG island of the TGF-b RI gene may account for loss of TGF-b responsiveness in human gastric cancers. Our results indicate that CpG island methylation is associated with inactivation of TGF-b type I receptor. We also show that transient transfection of a wild type TGF-b RI gene into SNU-601 cells resulted in an increased TGFb responsiveness, re¯ecting restoration of the TGF-b signaling pathway and demonstrating that the methylation of TGF-b RI gene represents the functional defect in the TGF-b signaling pathway of SNU-601.
Results

Methylation of the TGF-b type I receptor gene
Previous studies in this laboratory have shown that most of gastric cancer cell lines examined did not respond to TGF-b, indicating that the majority of these cells have escaped negative regulation of growth by TGF-b (Park et al., 1994) .
Among these cell lines, four lines (SNU-1, -484, -601 and -638) which have been shown to be resistant to TGF-b-mediated growth inhibition, and one TGF-bsensitive cell line (SNU-16) were included in this study. We also included one TGF-b-sensitive human colon adenocarcinoma cell line (Colo205). With the exception of the SNU-1 cell line, SNU-484 and -601 cell lines express a normal sized TGF-b RII transcript lacking mutations, and all of these cell lines express normalsized TGF-b RI transcripts (Figure 1 ). SNU-638 cell line contains mutation within the TGF-b RII polyadenine tract .
Since methylation of 5' CpG islands in the promoter regions of various genes is one established mechanism for regulating transcriptional activity (Bird, 1986; Jones, 1996) , we examined four gastric cancer cell lines for changes in DNA methylation. We used the previously identi®ed genomic sequence of the untranslated region of the ®rst exon of TGF-b RI gene (Bloom et al., 1996) and an additional 1190 bases upstream from the transcriptional start site (bases 71422/7232). Sequences around the transcriptional start site have a GC content of 66% and have a CpG/GpC ratio of 41 (Bloom et al., 1996) . As shown by the frequency of the CpG dinucleotide in Figure 2a , this island spans the part of ®rst exon.
A restriction map of the StyI fragment (7243/ 71421) reveals many methylation sensitive sites (Figure 2a ). Double digestion using restriction enzymes with the¯anking cut (StyI) and methylation sensitive enzymes (SmaI, HpaII and CfoI) shows that these sites were not methylated and that the methylation pattern was identical to the pattern seen in ®ve normal human gastric tissues, including the TGF-b-sensitive SNU-16 cell line and Colo205 human colon adenocarcinoma cell line (data not shown). In contrast, CpG sites (7953 and 7951) of the TGF-b RI promoter, which were recognized by BstUI, were completely methylated in two of these four gastric cancer cell lines, SNU-1 and SNU601, and partially methylated in the SNU-484 cell line and Colo205 cell line, whereas it was not methylated in the SNU-16 cell line and normal tissues (Figure 2c The same BstUI sites were methylated in ®ve of 40 (12.5%) primary tumors, but not in DNAs from normal tissues from the same patients, suggesting that this site is methylated in a tumor-speci®c manner ( Figure 2c ). Interestingly, these methylation sites are around the binding sites for the transcription factors Sp1 and KruÈ ppel-like transcription factors (Courey and Tjian, 1988; Kim et al., 1998; Miller and Bieker, 1993) . To map the exact methylation site in the promoter region of the TGF-b RI gene, we employed genomic sequencing. Primers were designed to amplify DNA after bisul®te treatment. We ampli®ed three fragments encompassing most of the CpG sites in the TGF-b RI promoter (from 71096 to 7939, from 7748 to 7268, and from 7390 to 7398) and sequenced these fragments. We could not ®nd the dierences in sequences following bisul®te treatment in the region between 7748 and 7398 in the TGF-b-sensitive SNU-16, TGF-b-resistant SNU-1, 7484, 7601 and 7719, and normal PBMC, whereas 7953 and 7951 cytosines within CpG dinucleotides in the 71096/7939 region were methylated in the TGF-b-resistant cell lines and primary tumors, but not in the TGF-b-sensitive SNU-16 cell line, PBMC, and normal gastric tissues ( Figure  3) . Following 5-aza-2'-deoxycytosine treatment, these same CpG sites were demethylated (data not shown). These results suggest that CpG sites located in sequences between 7953 and 7951 represent the cancer-speci®c methylation site.
Treatment of 5-aza-2'-deoxycytidine increased TGF-b RI transcription
Hypermethylation in the 5' promoter region is usually associated with suppression of transcription. We therefore examined the expression status of the TGF-b RI gene at the RNA level in gastric cancer cell lines with unmethylated and methylated TGF-b RI genes ( Figure  1 ). All four cell lines exhibiting hypermethylation of the TGF-b RI gene did express TGF-b RI transcripts as assessed by Northern blot analysis. The level of TGF-b RI transcript in the untreated SNU-484 cell line is highest among four cell lines exhibiting hypermethylation. This may be in part due to the fact that the TGF-b RI gene in this cell line is partially methylated (Figure 2c ). These observations suggest that loss or reduction of TGF-b RI expression limit the TGF-b response and lead to resistance to TGF-b.
In order to test the hypothesis that 5'CpG island methylation of the TGF-b RI gene suppresses gene expression, we treated these gastric cancer cells lines with the demethylating agent 5-aza-2'-deoxycytidine (0.1 ± 0 mM) for 5 days. As shown in Figure 1a (Figure 4a, lanes 7 and 8) .
Since 5-aza-2'deoxycytidine had profound eects on cell growth, we could not examine the eect of the enhanced expression of the TGF-b RI gene on the autocrine and paracrine growth regulatory activities by TGF-b in these cells. Therefore, to determine whether reduced expression of the TGF-b RI gene was responsible for blocking TGF-b signaling, a series of cellular transfection experiments was performed in SNU-601 cells because SNU-1 and SNU-638 cell lines contain mutations in the polyadenine tract of the TGF-b RII gene 
Discussion
In eukaryotic cells, methylation of CpG islands in the promoter regions of various genes is one established mechanism for regulating transcriptional activity (Bird, 1986; Jones, 1996) . Alterations of the pattern and regulation of DNA methylation are among the most consistent ®ndings in the development of human cancers (Issa et al., 1994; Herman et al., 1994) . De novo methylation of the Rb gene has been demonstrated in a small fraction of retinoblastomas, and aberrant methylation of the VHL gene was reported in a subset of sporadic renal cell carcinomas (Herman et al., 1994; Sakai et al., 1991) . Recently, inactivation of the E-cadherin gene and the CDKN2/p16/MTS1 gene by DNA methylation was shown in human carcinomas (Gonzalez-Zulueta et al., 1995; Merlo et al., 1995; Yoshiura, et al 1995) . It has been demonstrated that all mouse cell lines tested acquired de novo methylation of the MyoD CpG island during the establishment of immortal cell lines (Rideout et al., 1994) and there is also direct evidence that methylation errors occur in the estrogen receptor CpG island in apparently normal colonic epithelium in older individuals (Issa, 1994) .
We have previously shown that a majority of human gastric cancer cell lines have escaped from negative growth regulation by TGF-b (Park et al., 1994) . Gross structural alterations were demonstrated in the TGF-b RII gene in a majority of these resistant cell lines. We have now demonstrated that 5'CpG island methylation of TGF-b RI gene represents alternative pathway for inactivation of TGF-b signaling in human gastric cancers. We found the 5'CpG island methylation in cultured cells and primary tumors, suggesting that this speci®c form of methylation is a manifestation of the neoplastic transformation and not merely due to expansion of CpG methylation during cell culture. The fact that gastric cancer cell lines with the 5'CpG island methylation of the TGF-b RI gene still expresses low, but detectable amounts of TGF-b RI transcripts suggests the presence of other TGF-b RI transcriptional mechanisms which are not aected by the 5'CpG island methylation. We also cannot exclude the possibility that increased expression of TGF-b RI gene after 5-aza-2'-deoxycytidine treatment is in part due to transcriptional eects of 5-aza-2'-deoxycytidine on transcription factor(s) which regulates expression of TGF-b RI gene. Despite this low level of TGF-b RI expression, these cells are resistant to the growth inhibitory eects of TGF-b, suggesting that an appropriate ratio of TGF-b RI and TGF-b RII is required for the TGF-b signaling.
In a human colon cancer cell line which expresses low levels of RI and is only marginally sensitive to TGF-b, transfection of RI increased the eects of TGF-b on inhibition of growth and delayed tumorigenicity (Wang et al., 1996) . In this study, we show that cotransfection of SNU-601 cells with TGF-b RI, but not TGF-b RII, led to marked induction of the activity of a TGF-b-inducible luciferase reporter plasmid construct in response to TGF-b (Figure 4b ). These results suggest that the identi®ed 5'CpG island methylation of the TGF-b RI gene is directly responsible for the development of TGF-b resistance in SNU-601 cells.
The established role of the TGF-b signaling pathway in tumor suppression appears at odds with the observation that most human cancers, including liver, breast, and prostate cancers, in fact overexpress TGFb. One hypothesis that has been forwarded to explain this apparent contradiction is that overexpression occurs through active selection of tumor clones expressing higher levels of TGF-b and resistance to its eects (Reiss, 1997; Suardet et al., 1992; Wake®eld et al., 1991) . According to this theory, overexpression of TGF-b by the tumor confers a growth advantage through suppression of immune surveillance, promotion of angiogenesis, and/or stimulation of tumor stroma. Absence of a functional TGF-b receptor system in overexpressing cells is required the tumorigenic eects in this system by removing the tumor cells themselves from the growth suppressive eects of TGF-b. The ®ndings from this study are consistent with the possibility that TGF-b receptor defects in cancer cells contribute to malignant progression through an interruption in TGF-b-mediated autocrine growth inhibition. Finally, it is proposed that clones containing 5'CpG island methylation in the TGF-b RI gene may be selected during the process of malignant progression as a mechanism of escape from the autocrine eects of secretion of TGF-b.
Materials and methods
Cell lines and primary tumors
Cell lines are derived from gastric carcinoma specimens obtained at the time of surgery from individual patients (cells from either primary tumor specimens or malignant ascitic uid). These cell lines are kindly provided by Dr Jae-Gahb Park. Human colon adenocarcinoma cell line, Colo205, was purchased from ATCC (Rockville, MD, USA). Cells were maintained in RPMI medium 1640 supplemented with 10% (vol/vol) fetal bovine serum at 378C in an atmosphere of 5% CO 2 and 95% air. CCL-64 mink lung epithelial cells were maintained in DMEM supplemented with 10% fetal bovine serum. Forty human gastric tumor samples and their matched normal counterparts were obtained at the time of surgery from gastric cancer patients. None of the patients had received either chemotherapy or radiotherapy prior to surgery. Frozen tissue samples were stored until use at 7708C
Southern blot analysis for TGF-b methylation
Genomic DNA was extracted from human gastric cancer cells or primary human gastric carcinomas by using standard proteinase K method. Ten mg of DNA was digested with 40 units of StyI and then with methylation-sensitive restriction endonuclease, either HpaII, SmaI, CfoI, or BstUI for 16 h. Digested DNA was fractionated on a 1.2% agarose gel and transferred to a positive charged nylon membrane (Nytranplus; Schleicher and Schuell). Blots were hybridized with 32 Plabeled RI promoter (Bloom et al., 1996) probes (probe A: 165 bp, beginning at nucleotide 358, GenBank sequence accession No. U51139, probe B: 802 bp, beginning at 553) in 50% formamide/66SSC/1% SDS at 428C for 20 h. Probe A was obtained by PCR using normal genomic DNA from human peripheral blood and digestion with EcoRI. Probe B was kindly provided by Dr RH Goldstein.
Bisul®te modi®cation and genomic sequencing
Genomic DNA from gastric cancer cell lines was modi®ed by bisul®te treatment and puri®ed as previously described (Clark et al., 1994; Herman et al., 1996) . To obtain products for sequencing (see Figure 1) , PCR ampli®cations were performed in 25 ml reaction mixtures containing 0.1 mg of bisul®te-treated genomic DNA, 200 mM dNTP, 1 mM primers, 16.6. mM ammonium sulfate, 67 mM Tris-HCl (pH 8.8), 6.7 mM MgCl 2 , 10 mM 2-mercamtoethanol, 5% dimethylsulfoxide and 1 U of AmpliTaq Gold DNA polymerase (PerkinElmer). Primers used for ampli®cation of bisulfate-treated DNA were: RI-327 sense, 5'-AAGGTGGGTG-GAGTGTTTTGTA-3'/RI-484 antisense, 5'-CACCCAAC-TCCCACAAAACAAA-3'; RI-675 sense, 5'-TTGGGTTT-GGAATTGGGTGG-3/RI-1155 antisense, 5'-CACCCCA-CACTCCCCAAAAA-3'; RI-1033 sense, 5'-TGGGG-TTAGTGGTTGAGTGGTGT-3'/RI-1358 antisense, 5'-CACCTCACCCCACCTCCCT-3'. The ampli®ed fragments were cloned into pCR2.1-TOPO plasmid using TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA). Sequencing reactions were carried out manually using Sequenase version 2.0 DNA sequencing kit (Amersham Life Science, Cleveland, OH, USA) or using ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer) with AmpliTaq DNA polymerase, FS (Perkin Elmer) and the automated 373A DNA Sequencer (Applied Bisystem).
Northern blot analysis
Total RNA was isolated from cells with guanidium isothiocyanate/phenol/chloroform. Poly(A) RNA was further extracted using Oligotex mRNA extraction kit (QIAGEN, Hilden, Germany) according to the manufacturer's instruction. Two mg of poly(A) RNA was electrophoresed on a 1.0% agarose gel containing 0.66 M formaldehyde, transferred to a Duralon-UV membrane, and cross-linked with a UV Stratalinker (Stratagene). Blots were hybridized with cDNA probes for human TGF-b type I and II receptors (FranzeÂ n et al., 1993; Lin et al., 1992) .
Run-on transcription
All conditions used in the nuclear run-on assays were according to Greenberg (1987) . Nuclei were isolated from SNU-16 or SNU-601 cells treated with or without 5 mM 5-aza-2'-deoxycytidine treatment for 5 days. Elongation of RNA from 2610 7 nuclei was done in the presence of 250 mCi of [ 32 P]UTP (3000 Ci/mmol). Each labeled RNA sample (10 7 c.p.m.) was then hybridized to plasmids (10 mg) bound to Nytran through a dot blot apparatus. Hybridization was for 30 h at 658C, and washes were done in two 15-min steps with 26SSC (SSC is 0.15 M NaCl plus 0.015 M sodium citrate) and 0.26SSC at 658C.
Receptor cross-linking
Cells were plated at a density of 1610 6 cells/well in 6-well dishes. Receptor cross-linking assay was performed as described previously (Chang et al., 1997) . and RII (C-16) antibodies for immunoprecipitation were purchased from Santa Cruz Biotechnology, CA, USA.
Cell transfection
For transient expression assays, cells were plated at 0.3610 6 per well in 6-well dishes, then were transfected with a promoter construct, 3TP-Lux, which contains multiple copies of TGF-b response elements, using lipofectin (Life Technologies, Inc.). After 5 h, complete medium was added, cells were incubated for 24 h, then were treated with 10 ng/ml of TGF-b and incubated an additional 24 h. Luciferase activity was assayed. All assays were repeated a minimum of three times, and similar results were obtained each time. Activity was normalized on the basis of b-galactosidase expression from pSVb-galactosidase in all luciferase reporter experiments.
Abbreviations TGF-b, transforming growth factor-b; RII, type II receptor; RI, type I receptor; PCR, polymerase chain reaction
